Regeneron stays at neutral by Merrill

Regeneron Pharmaceuticals Inc.'s rating remained unchanged at neutral by Merrill Lynch analyst Hari Sambasivam. The company reported total revenues of $18.2 million, compared with Merrill's estimate of $17.6 million. Net loss was reported at $20.4 million, or $0.36 per share, versus the analyst's estimate of $35.8 million, or $0.64 per share, the same as consensus. Merrill cut its earnings-per-share estimate for 2006 to $1.98 from $2.25. Shares of the Tarrytown, N.Y., biotechnology company were down 17 cents, or 1.11%, at $15.17 on volume of 302,955 shares versus the three-month running average of 386,490 shares. (Nasdaq: REGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.